Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Hers vs PlexusDx

Hers
Graded #252

Lower grade

vs+3.8000000000000043
PlexusDx
Graded #162

Higher grade

The verdict

PlexusDx takes it — 67.7/100 to 63.9/100.

PlexusDx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. PlexusDx (plexusdx.com) is a US GLP-1 telehealth platform offering compounded weight-loss medications with licensed providers in all 50 states.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valuePlexusDx +20
54
74
Dose & formulationHers +13
77
64
Clinical oversightPlexusDx +3
71
74
Labs & monitoringEven
52
52
FulfillmentHers +3
81
78
Contract termsPlexusDx +14
41
55
Hers · left barPlexusDx · right bar

The numbers

MetricHersPlexusDx
WeighScore63.9/10067.7/100
GradeCC
Scorecard rank#252#162
Semaglutide$199/mo (starting dose, compounded)$149/mo (starting dose, compounded)
Tirzepatide$299/mo (starting dose, plus a separate fee, brand-name)$249/mo (starting dose, compounded)
CoverageAll 50 statesAll 50 states
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyInjection only
Hers

Graded #252 · C

Strengths

  • Compounded GLP-1 access

Where it loses points

  • Limited public information on program details
PlexusDx

Graded #162 · C

Strengths

  • Licensed providers available in all 50 states
  • Range of options including low-cost microdose GLP-1 from $129/mo
  • Optional Precision Peptide genetic panel adds a personalization angle
  • Independent clinician review via state-licensed telehealth platform
  • Compounded medications from state-licensed pharmacies

Where it loses points

  • Compounded medications only; no FDA-approved brand options
  • Specific compounding pharmacies not named
  • Genetic-panel upsell may not add clinical value for everyone
  • Tirzepatide pricing from $249/mo is higher than budget rivals
  • No insurance accepted

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard